Capstone Headwaters advised Revolutionary Medical Devices, Inc. (RMD), a maker of innovate products for airway management, focused on significantly improving patient outcomes, on its sale to Vyaire Medical Inc., the healthcare industry’s dedicated “breathing company”. Terms of the transaction were not disclosed.
RMD’s main product, the SuperNO2VA™ device, is a complete noninvasive nasal PAP ventilation system designed for use in the treatment of respiratory insufficiency from collapse of the airway during or after sedation, or during the intubation process. The SuperNO2VA™ system effectively opens the upper airway, maintains patency, and allows the anesthesiologist to effectively ventilate the patient. It is designed to reduce the likelihood of respiratory compromise via perioperative hypoxemia, particularly with “high risk” patients who may be presented with difficult airways.
The SuperNO2VA™ system can also be used to pre-oxygenate, relieve UAO, maintain ventilation, and rescue ventilate, as well as for intra-oral procedures. It can also be used peri-operatively. The system, which functions with an air-tight mask over the patient’s nose, allows for the use of positive pressure within the mask to help maintain an open airway that allows for continuous nasal oxygenation and ventilation throughout sedation.
Vyaire management sees the acquisition of RMD as another step toward the company’s stated goal of becoming the global leader in the respiratory care market.
Revolutionary Medical Devices, Inc. (RMD) was established in 2013. Since inception, RMD has focused on developing innovative technologies to improve patient outcomes and increase efficiency with regard to airway management. For more information, visit .
Headquartered in Chicago, IL., Vyaire Medical supports and improves the lives of patients with a laser focus on improving patient outcomes and increasing value for customers. The company was formed in October 2016, to serve healthcare customers with innovative device and service solutions across the respiratory and anesthesia continua of care. Vyaire’s legacy brands have a 65-year track record of pioneering, innovating, and advancing respiratory diagnostics, ventilation, and anesthesia delivery & patient monitoring.
David Baker, Managing Director at Capstone Headwaters, said
“We were highly interested to work with RMD since they met all the criteria a strategic buyer would seek in an acquisition. RMD had an FDA-cleared product, superior clinical results, high margins, and a very large global market opportunity”,
Dave Kane, CEO of Revolutionary Medical Devices, Inc., stated
“Capstone Headwaters executed an effective process that resulted in a superior outcome for RMD shareholders. David Baker understands the mindset of strategic buyers and how to manage towards an optimal result.”